Similar results were obtained among MBC patients; however, it was noteworthy that PR (HR = 0.68, 95% CI: 0.35–1.31) and HER-2 status (HR = 0.95, 95% CI: 0.55–1.63) did not appear to independently influence cancer-related survival (Table 2). The gene discussed is ERBB2; the disease is cancer.